Welcome to Evalve

Evalve was incorporated in 1999 to design, develop, manufacture and market innovative devices to enable percutaneous repair of cardiac valves. The company’s initial products are intended to reduce the risks, trauma and cost associated with current open, arrested heart surgical options. The company’s present development and clinical efforts are focused on mitral valve repair.

Mitral regurgitation is the most common type of heart valve insufficiency in the United States; Approximately 4 million people have significant mitral valve insufficiency, with an annual incidence of 250,000. Approximately 50,000 of these patients undergo surgery each year in the United States. Prevalence and incidence are similar in Europe, where it’s the second most common type of heart valve disease. The disease affects millions of people worldwide.

Mitral regurgitation, if left untreated, is associated with chronic volume overload, which ultimately leads to atrial fibrillation, heart muscle dysfunction, symptoms of congestive heart failure (CHF) and an increased risk of sudden death. Improved treatment options for people with valvular insufficiency may reduce the potential for developing CHF and may improve the quality of life for those currently suffering from CHF.

Evalve obtained CE mark approval in 2008 for the MitraClip^® system, the world’s first percutaneous valve repair system.